Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The benefits of PET in the prognosis and treatment of HL

Peter Borchmann • 11 Jun 2022
EHA 2022
Hodgkin Lymphoma Lymphoma Non-Hodgkin Lymphoma Bleomycin Cyclophosphamide Dacarbazine Doxorubicin Etoposide Prednisone Procarbazine Vinblastine Vincristine
HD17 HD18

Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the applications of PET-CT in the prognosis and management of Hodgkin lymphoma (HL). Prof. Borchmann comments on how using PET allows for treatment personalization, and how total metabolic tumor volume (MTV) determination using PET is highly prognostic of patient outcomes. Moreover, the Phase III HD17 and HD18 trials (NCT01356680, NCT00515554) are discussed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Peter Borchmann

1:34
PET-guided treatment: the new standard of care in Hodgkin lymphoma?
Peter Borchmann • 15 Jun 2023
1:26
Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
Peter Borchmann • 15 Jun 2023
2:27
Insights into the BrECADD regimen in HL & results from the GHSG HD21 study
Peter Borchmann • 15 Jun 2023
5:02
HD21: treatment-related morbidity in patients with Hodgkin lymphoma treated with BrECADD vs eBEACOPP
Peter Borchmann • 12 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals